The cancer-immunity cycle (C-IC) concept has clearly demonstrated the mechanisms of immune cells to attack and kill tumors through CD8+ T-cell cytotoxicity (11) and represented a basis for understanding the present state of cancer immunotherapy, contributing to drug selection and combination therapies for patients refractory to ICIs and conventional therapies (12, 13). This evidence concerns the gene CD8A and cancer.